SCHEMBL9628332

SCHEMBL9628332

CCN(CC)CCCNC(=O)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.64
TDP1 Q9NUW8 1/20 0.63
DRD2 P14416 1/20 0.62
DRD4 P21917 1/20 0.62
DRD3 P35462 1/20 0.62
GAA P10253 1/20 0.61
LMNA P02545 3/20 0.59
TSHR P16473 2/20 0.59
ALDH1A1 P00352 2/20 0.59
SLC22A2 O15244 1/20 0.59
SLC22A1 O15245 1/20 0.59
ACHE P22303 1/20 0.59
MAPK1 P28482 1/20 0.59
CYP2C19 P33261 1/20 0.59
APP P05067 1/20 0.58
BLM P54132 1/20 0.57
PMP22 Q01453 1/20 0.57
HDAC1 Q13547 3/20 0.57
HDAC2 Q92769 3/20 0.57
HDAC8 Q9BY41 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542239 0.90 TDP1 (0.74) NAAATDP1LMNATSHRALDH1A1
SCHEMBL4551634 0.90 GAA (0.61) NAAATDP1DRD2DRD4DRD3
SCHEMBL13875528 0.89 SMN1; SMN2 (0.69) TDP1GAALMNATSHRALDH1A1
Hydrochloric Acid SCHEMBL7576777 0.89 TDP1 (0.72) NAAATDP1LMNATSHRALDH1A1
SCHEMBL23786281 0.88 TDP1 (0.65) NAAATDP1DRD2DRD4DRD3
SCHEMBL14679112 0.86 L3MBTL1 (0.65) DRD2DRD4DRD3GAALMNA
SCHEMBL28274478 0.86 LMNA (0.61) DRD2DRD4DRD3LMNATSHR
SCHEMBL9259700 0.86 SMN1; SMN2 (0.65) GAAALDH1A1ACHEMEN1CYP2D6
SCHEMBL9364516 0.84 POLB (0.71) DRD2DRD4DRD3LMNATSHR
SCHEMBL14797432 0.84 LMNA (0.56) DRD2DRD4DRD3GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0145654-B2 METHOD OF LINING THE INSIDES OF PIPES OR PARTS OF PIPES CIBA-GEIGY AG (CH) 1992-05-13 EP claimed
US-4762585-A EPOXY RESINS WITH AMINE CURING AGENTS CIBA-GEIGY CORPORATION (US) 1988-08-09 US claimed
EP-0145654-B1 METHOD OF LINING THE INSIDES OF PIPES OR PARTS OF PIPES CIBA-GEIGY AG (CH) 1987-11-25 EP claimed
EP-0145654-A1 Method of lining the insides of pipes or parts of pipes CIBA-GEIGY AG (CH) 1985-06-19 EP claimed
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
EP-4129282-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-02-08 EP disclosed
CN-115427032-A Pharmaceutical composition and use thereof 浙江养生堂天然药物研究所有限公司 2022-12-02 CN disclosed
EP-0145654-B2 METHOD OF LINING THE INSIDES OF PIPES OR PARTS OF PIPES CIBA-GEIGY AG (CH) 1992-05-13 EP disclosed
US-4845234-A IN SITU LINING OF PIPE INTERIORS, CURING AGENTS FOR EPOXY RESINS CIBA-GEIGY CORPORATION (US) 1989-07-04 US disclosed
US-4762585-A EPOXY RESINS WITH AMINE CURING AGENTS CIBA-GEIGY CORPORATION (US) 1988-08-09 US disclosed
EP-0145654-B1 METHOD OF LINING THE INSIDES OF PIPES OR PARTS OF PIPES CIBA-GEIGY AG (CH) 1987-11-25 EP disclosed
EP-0145654-A1 Method of lining the insides of pipes or parts of pipes CIBA-GEIGY AG (CH) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 NAAA 4790/4885TDP1 3665/4885DRD2 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.